Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

November 10, 2026 updated by: Beijing InnoCare Pharma Tech Co., Ltd.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

182

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Anhui
      • Wuhu, Anhui, China, 241001
        • The Second Affiliated Hospital of Wannan Medical College
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100005
        • Beijing Tongren Hospital, Affiliated to Capital Medical University
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400011
        • Chongqing Traditional Chinese Medicine Hospital
    • Fujian
      • Fuzhou, Fujian, China, 350005
        • Fujian Medical University First Affiliated Hospital
    • Guangdong
      • Guangzhou, Guangdong, China, 510091
        • Dermatology Hospital of Southern Medical University
      • Shenzhen, Guangdong, China, 518020
        • Shenzhen People's Hospital
    • Hebei
      • Shijiazhuang, Hebei, China, 230601
        • The Second Hospital of Hebei Medical University
    • Henan
      • Luoyang, Henan, China, 450000
        • The Second Affiliated Hospital of Henan University of Science and Technology
      • Zhengzhou, Henan, China, 471000
        • Henan Provincial People's Hospital
    • Hubei
      • Jingzhou, Hubei, China, 434020
        • Jingzhou Central Hospital
    • Hunan
      • Changsha, Hunan, China, 410008
        • Xiangya Hospital of Central South University
    • Jiangsu
      • Suzhou, Jiangsu, China, 215002
        • Suzhou Municipal Hospital
      • Zhenjiang, Jiangsu, China, 212001
        • Affiliated Hospital of Jiangsu University
    • Shandong
      • Jinan, Shandong, China, 250012
        • Qilu Hospital of Shandong University
      • Jinan, Shandong, China, 250022
        • Shandong Provincial Hospital of Dermatology
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200040
        • Huashan Hospital Affiliated to Fudan University
      • Shanghai, Shanghai Municipality, China, 200443
        • Shanghai Dermatology Hospital
    • Sichuan
      • Chengdu, Sichuan, China, 610000
        • Chengdu Second People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300120
        • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    • Yunnan
      • Kunming, Yunnan, China, 650000
        • The First Affiliated Hospital of Kunming Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310006
        • Hangzhou First People's Hospital
      • Hangzhou, Zhejiang, China, 310009
        • Hangzhou Third People's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).

  2. Male or female subjects aged ≥ 18 years and ≤ 70 years

  3. A history of plaque psoriasis for ≥6 months at baseline

  4. Meet the following three criteria:

    1. Psoriasis Area and Severity Index (PASI) score ≥12
    2. Static Physician's Global Assessment (sPGA) score ≥3
    3. Psoriasis affected Body Surface Area (BSA) ≥10%
  5. The subject requires systemic treatment and/or phototherapy.

Exclusion Criteria:

  1. Diagnosed with non-plaque psoriasis.
  2. Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
  3. Presence of clinically serious, progressive, or uncontrolled disease.
  4. Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
  5. Pregnant or lactating women.
  6. The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ICP-332 Dose A

ICP-332 will be administered as tablet for 12 weeks

Experimental: ICP-332 Dose B

ICP-332 will be administered as tablet for 12 weeks

Experimental: ICP-332 Dose C

ICP-332 will be administered as tablet for 12 weeks

Placebo Comparator: ICP-332 Placebo

Placebo will be administered as tablet for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) at Week 12
Time Frame: Day 1 to Day 85
Day 1 to Day 85

Secondary Outcome Measures

Outcome Measure
Time Frame
Percentage of Participants With PASI-50, PASI-75, PASI-90, PASI-100 on scheduled Visit(except W12 PASI 75)
Time Frame: Day 1 to Day 85
Day 1 to Day 85
Percentage of Participants at Week12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)
Time Frame: Day 1 to Day 85
Day 1 to Day 85
Number of Participants With Adverse Events
Time Frame: Day 1 to Day 113
Day 1 to Day 113
The peak concentration (Cmax)
Time Frame: Day 1, Day15, Day 29, Day 57
Day 1, Day15, Day 29, Day 57
The time to peak (Tmax)
Time Frame: Day 1, Day15, Day 29, Day 57
Day 1, Day15, Day 29, Day 57
The half-life (t1/2)
Time Frame: Day 1, Day15, Day 29, Day 57
Day 1, Day15, Day 29, Day 57
The area under the blood concentration-time curve (AUC0-∞ and AUC0-t)
Time Frame: Day 1, Day15, Day 29, Day 57
Day 1, Day15, Day 29, Day 57

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Yuling Shi, Shanghai Dermatology Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 22, 2025

Primary Completion (Actual)

October 30, 2026

Study Completion (Actual)

October 30, 2026

Study Registration Dates

First Submitted

November 19, 2025

First Submitted That Met QC Criteria

November 19, 2025

First Posted (Actual)

November 26, 2025

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ICP-CL-00603

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.